Literature DB >> 12235168

Metabolic origins and clinical significance of LDL heterogeneity.

Kaspar K Berneis1, Ronald M Krauss.   

Abstract

LDLs in humans comprise multiple distinct subspecies that differ in their metabolic behavior and pathologic roles. Metabolic turnover studies suggest that this heterogeneity results from multiple pathways, including catabolism of different VLDL and IDL precursors, metabolic remodeling, and direct production. A common lipoprotein profile designated atherogenic lipoprotein phenotype is characterized by a predominance of small dense LDL particles. Multiple features of this phenotype, including increased levels of triglyceride rich lipoprotein remnants and IDLs, reduced levels of HDL and an association with insulin resistance, contribute to increased risk for coronary heart disease compared with individuals with a predominance of larger LDL. Increased atherogenic potential of small dense LDL is suggested by greater propensity for transport into the subendothelial space, increased binding to arterial proteoglycans, and susceptibility to oxidative modification. Large LDL particles also can be associated with increased coronary disease risk, particularly in the setting of normal or low triglyceride levels. Like small LDL, large LDL exhibits reduced LDL receptor affinity compared with intermediate sized LDL. Future delineation of the determinants of heterogeneity of LDL and other apoB-containing lipoproteins may contribute to improved identification and management of patients at high risk for atherosclerotic disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12235168     DOI: 10.1194/jlr.r200004-jlr200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  202 in total

Review 1.  The effect of chronic kidney disease on lipid metabolism.

Authors:  Neris Dincer; Tuncay Dagel; Baris Afsar; Adrian Covic; Alberto Ortiz; Mehmet Kanbay
Journal:  Int Urol Nephrol       Date:  2018-12-05       Impact factor: 2.370

2.  Conversion of lipid transfer inhibitor protein (apolipoprotein F) to its active form depends on LDL composition.

Authors:  Richard E Morton; Diane J Greene
Journal:  J Lipid Res       Date:  2011-09-21       Impact factor: 5.922

3.  Effects of insulin sensitivity, body composition, and fitness on lipoprotein particle sizes and concentrations determined by nuclear magnetic resonance.

Authors:  Brian A Irving; K Sreekumaran Nair; Manivannan Srinivasan
Journal:  J Clin Endocrinol Metab       Date:  2011-01-26       Impact factor: 5.958

4.  Low Plasma Hdl Cholesterol and Elevated C Reactive Protein further Increase Cardiovascular Disease Risk in Latinos with Type 2 Diabetes.

Authors:  Mariana C Calle; Sonia Vega-López; Sofia Segura-Pérez; Jeff S Volek; Rafael Pérez-Escamilla; Maria Luz Fernandez
Journal:  J Diabetes Metab       Date:  2010-11-10

Review 5.  Low-density lipoprotein particle number and risk for cardiovascular disease.

Authors:  William C Cromwell; James D Otvos
Journal:  Curr Atheroscler Rep       Date:  2004-09       Impact factor: 5.113

6.  Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib.

Authors:  Ronald M Krauss; Kathleen Wojnooski; Joseph Orr; J Casey Geaney; Cathy Anne Pinto; Yang Liu; John A Wagner; Julie Mabalot Luk; Amy O Johnson-Levonas; Matt S Anderson; Hayes M Dansky
Journal:  J Lipid Res       Date:  2011-12-17       Impact factor: 5.922

7.  Changes in lipoprotein(a), oxidized phospholipids, and LDL subclasses with a low-fat high-carbohydrate diet.

Authors:  Nastaran Faghihnia; Sotirios Tsimikas; Elizabeth R Miller; Joseph L Witztum; Ronald M Krauss
Journal:  J Lipid Res       Date:  2010-08-16       Impact factor: 5.922

8.  Using apolipoprotein B to manage dyslipidemic patients: time for a change?

Authors:  Charles R Harper; Terry A Jacobson
Journal:  Mayo Clin Proc       Date:  2010-05       Impact factor: 7.616

9.  Electronegative low-density lipoprotein is associated with dense low-density lipoprotein in subjects with different levels of cardiovascular risk.

Authors:  Ana Paula de Queiroz Mello; Isis Tande da Silva; Aline Silva Oliveira; Valéria Sutti Nunes; Dulcineia Saes Parra Abdalla; Magnus Gidlund; Nágila Raquel Teixeira Damasceno
Journal:  Lipids       Date:  2010-06-24       Impact factor: 1.880

10.  Triglyceride-Rich Lipoprotein Cholesterol, Small Dense LDL Cholesterol, and Incident Cardiovascular Disease.

Authors:  Edward K Duran; Aaron W Aday; Nancy R Cook; Julie E Buring; Paul M Ridker; Aruna D Pradhan
Journal:  J Am Coll Cardiol       Date:  2020-05-05       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.